DE60326226D1 - Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom - Google Patents

Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom

Info

Publication number
DE60326226D1
DE60326226D1 DE60326226T DE60326226T DE60326226D1 DE 60326226 D1 DE60326226 D1 DE 60326226D1 DE 60326226 T DE60326226 T DE 60326226T DE 60326226 T DE60326226 T DE 60326226T DE 60326226 D1 DE60326226 D1 DE 60326226D1
Authority
DE
Germany
Prior art keywords
prostaglandin
glaucoma
treatment
combination
antimicrobial agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60326226T
Other languages
English (en)
Inventor
Kirk M Maxey
Jennifer Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cayman Chemical Co Inc
Original Assignee
Cayman Chemical Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cayman Chemical Co Inc filed Critical Cayman Chemical Co Inc
Application granted granted Critical
Publication of DE60326226D1 publication Critical patent/DE60326226D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE60326226T 2002-03-21 2003-03-21 Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom Expired - Lifetime DE60326226D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36707102P 2002-03-21 2002-03-21
PCT/US2003/008935 WO2003079997A2 (en) 2002-03-21 2003-03-21 Prostaglandin f2 alpha analogs in combinaiotn with antimicrobials for treating glaucoma

Publications (1)

Publication Number Publication Date
DE60326226D1 true DE60326226D1 (de) 2009-04-02

Family

ID=28454834

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60326226T Expired - Lifetime DE60326226D1 (de) 2002-03-21 2003-03-21 Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom

Country Status (7)

Country Link
US (1) US20060264353A1 (de)
EP (1) EP1501530B1 (de)
JP (1) JP2005526092A (de)
AT (1) ATE422894T1 (de)
AU (1) AU2003222049B2 (de)
DE (1) DE60326226D1 (de)
WO (1) WO2003079997A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7060808B1 (en) * 1995-06-07 2006-06-13 Imclone Systems Incorporated Humanized anti-EGF receptor monoclonal antibody
US20030224001A1 (en) * 1998-03-19 2003-12-04 Goldstein Neil I. Antibody and antibody fragments for inhibiting the growth of tumors
ZA200007412B (en) * 1998-05-15 2002-03-12 Imclone Systems Inc Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
EP1218032A4 (de) * 1999-05-14 2005-05-25 Imclone Systems Inc Behandlung von refraktären humanen tumoren mit antagonisten des epidermalen wachstumsfaktorrezeptors
AU9500201A (en) * 2000-08-09 2002-02-18 Imclone Systems Inc Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists
US20080008704A1 (en) * 2001-03-16 2008-01-10 Mark Rubin Methods of treating colorectal cancer with anti-epidermal growth factor antibodies
EP1622941A2 (de) * 2003-03-20 2006-02-08 ImClone Systems Incorporated Methode zur produktion von anti-egfr antikörpern
MXPA06010715A (es) * 2004-03-19 2007-05-23 Imclone Systems Inc Anticuerpo del receptor del factor de crecimiento humano anti-epidermico.
US20070015838A1 (en) * 2005-07-14 2007-01-18 Allergan, Inc. Cyclopentane n-lower alkyl heptenamide-5-cis-2-(3alpha-hydroxy-5-phenylpentyl)-3, 5-dihydroxy, [1alpha, 2beta, 3alpha, 5alpha] compounds as agents for lowering intraocular pressure
US8138148B2 (en) 2005-08-16 2012-03-20 Copenhagen University GDNF derived peptides
EP1941876A1 (de) * 2006-12-28 2008-07-09 Lacer, S.A. Isosorbidmononitrit Derivate zur Behandlung von der Inflammation und okularen Hypertension
ES2671372T3 (es) * 2007-07-26 2018-06-06 Azad Pharma Ag Preparaciones farmacéuticas que comprenden disoluciones de hipoclorito activadas electroquímicamente
MX2010007442A (es) 2008-01-07 2010-12-21 Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg Uso de peptidos para promover la curacion de heridas.
US9090670B2 (en) 2008-01-07 2015-07-28 Rapid Pathogen Screening, Inc. Use of peptides for promoting wound healing
EP2288333B1 (de) * 2008-05-14 2011-12-28 Peter Thomas Roth Labs, Llc Auf prostaglandin basierende zusammensetzung und verfahren zu ihrer verwendung
DE102009007381A1 (de) * 2009-01-29 2010-08-05 Amp-Therapeutics Gmbh & Co. Kg Antibiotische Peptide
CA2773737C (en) 2009-09-09 2021-11-16 Pharmain Corporation Anionic-core composition for delivery of therapeutic agents, and methods of making and using the same
US20130310327A1 (en) 2012-05-18 2013-11-21 Rapid Pathogen Screening, Inc. Histatin for Corneal Wound Healing and Ocular Surface Disease
WO2015048736A1 (en) * 2013-09-30 2015-04-02 Irix Pharmaceuticals, Inc. Novel synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
CA2935957C (en) 2014-01-10 2023-01-03 Manistee Partners Llc Treatment of migraines using topical administration of prostaglandin f2alpha analogs
CN106456710A (zh) * 2014-06-20 2017-02-22 库柏维景国际控股公司 用于治疗眼部感染的眼用组合物
IT201700006360A1 (it) * 2017-01-20 2018-07-20 Italdevice Srl Composizione per uso oftalmico
AU2022359566A1 (en) * 2021-10-08 2024-02-29 Bonafide Health, Llc Products and methods for extending the shelf life of water-sensitive products

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025516A (en) * 1975-06-23 1977-05-24 The John C. Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
US4116979A (en) * 1975-06-23 1978-09-26 Sheehan Institute For Research, Inc. Process for the preparation of (-)-6a,10a-trans-6a,7,8,10a-tetrahydrodibenzo[b,d]-pyrans
US4049678A (en) * 1976-03-29 1977-09-20 The Upjohn Company 9-Deoxy-PGD-type, 1,15-lactones
US4032543A (en) * 1975-06-23 1977-06-28 The Upjohn Company Pg-type 1,11-lactones
JP3361830B2 (ja) * 1992-03-30 2003-01-07 生化学工業株式会社 抗菌性組成物及びそれを有効成分とする薬剤
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5643875A (en) * 1994-01-24 1997-07-01 Friedmann; Nadav Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products
US5652209A (en) * 1994-04-29 1997-07-29 University Of Miami Use of secretory products of human lacrimal gland acinar epithelia for tear replacement therapy
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
ATE326972T1 (de) * 1997-10-13 2006-06-15 R Tech Ueno Ltd Heilende zusammensetzung für intraokulare hypertension oder glaukom
WO2002000839A2 (en) * 2000-06-28 2002-01-03 The Regents Of The University Of California Statement as to federally sponsored research
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
AR035541A1 (es) * 2000-11-13 2004-06-16 Pharmacia Ab Un metodo de tratamiento para pacientes que sufren de glaucoma severo o necesitan una reduccion de la presion intraocular (pio) y el uso de una combinacion de agentes reductores de la pio

Also Published As

Publication number Publication date
WO2003079997A3 (en) 2004-02-12
EP1501530A2 (de) 2005-02-02
ATE422894T1 (de) 2009-03-15
JP2005526092A (ja) 2005-09-02
AU2003222049B2 (en) 2007-05-31
EP1501530A4 (de) 2006-05-03
US20060264353A1 (en) 2006-11-23
WO2003079997A2 (en) 2003-10-02
AU2003222049A1 (en) 2003-10-08
EP1501530B1 (de) 2009-02-18

Similar Documents

Publication Publication Date Title
DE60326226D1 (de) Prostaglandin f2 alpha analoga in kombination mit einem antimikrobiellen mittel zur behandlung von glaukom
DE69434228D1 (de) Verwendung von Fluprostenolisopropylester zur Herstellung eines Arzneimittels zur Behandlung von Glaukom und okularer Hypertension
ES2178291T3 (es) Uso de acidos 3-benzoil-aceticos, esteres, o amidas para el tratamiento del glaucoma glc1a.
BR0310047A (pt) Análogos de 8-azaprostaglandina como agentes para diminuição de pressão intra-ocular
WO2000027424B1 (en) Upregulation of endogenous prostaglandins to lower intraocular pressure
BR0209709A (pt) Composições hipotensivas de lipìdio e timolol e métodos de uso das mesmas
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
NO20006544D0 (no) C-terminalt modifiserte oksamyldipeptider som inhibitorer av ICE/ced-3 familien av cystein proteaser
EP2325651A3 (de) Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung
CA2613464A1 (en) Treatment of dry eye
RU2004134733A (ru) Агенты, которые регулируют, ингибируют или модулируют активность и/или экспрессию факторов роста соединительной ткани (фрст), в качестве уникальных средств для снижения внутриглазного давления и лечения глаукоматозных ретинопатий/оптических невропатий
DE69719931D1 (de) Verwendung von Acetylcystein zur Herstellung eines Arzneimittels zur Behandlung von chronischen Geschwüren
EP0824910A3 (de) Verwendung eines Krill-Enzyms zur Behandlung von Zahnbelag
WO2003072066A3 (en) Compositions and methods for the treatment of glaucoma and ocular hypertension
ATE169815T1 (de) Ophthalmische zusammensetzungen enthaltend als wirkstoff vitamin-e oder ester davon
DE60219614D1 (de) 3, 7 thiaprostansäurederivate als mittel zur verminderung des augeninnendruckes
FR2754712B1 (fr) Compositions ophtalmiques
ATE453395T1 (de) 3, 7 oder 3 und 7 thia- oder oxaprostansäure derivate als mittel zur senkung des augeninnendrucks
BR0315864A (pt) Composições e processos para a modificação efeitos tóxicos de compostos proteináceos
AU631738B2 (en) Bis(alkyl-substituted-4-hydroxyphenylthio)alkane analogs as inhibitors of cataractogenesis
ATE216889T1 (de) Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension
EP2062872A3 (de) Verwendung von Bisaminen zur Verstärkung der antimikrobiellen Wirkung von wässrigen Zusammensetzungen
DE69834638D1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
WO1995034302A3 (en) Method for reducing intraocular pressure in the mammalian eye by administration of calcium chelators
WO2006136175A3 (en) Pharmaceutical compositions comprising tacrolimus and a cyp3a4 inhibitor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition